Results 251 to 260 of about 93,268 (298)

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

Arthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher, Iain B. McInnes, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Elena Reynoso, Warner Chen, Maoji Li, Lianne S. Gensler, Philip J. Mease, Christopher T. Ritchlin   +12 more
wiley   +1 more source

Integrated microfluidics-based construction of anti-BTN2A2 gel droplet cell preparations for non-invasive tumor-infiltrating lymphocyte therapy. [PDF]

Mater Today Bio
Tian Y, Li J, Yang N, Zhao Y, Zuo J, Xiong H, Pan Y, Xiao L, Su M, Han F, He Z, Hu R.   +11 more
europepmc   +1 more source

Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study. [PDF]

J Clin Oncol
Medina T, Chesney JA, Kluger HM, Hamid O, Whitman ED, Cusnir M, Thomas SS, Wermke M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Larkin J, Weber J, Graf Finckenstein F, Chou J, Gastman B, Wu X, Fiaz R, Sarnaik AA, C-144-01 Investigators.   +19 more
europepmc   +1 more source

The impact of the tumor immune microenvironment and tumor-infiltrating lymphocyte subgroups on laryngeal cancer prognosis. [PDF]

Sci Prog
Tevetoğlu F, Çomunoğlu N, Yener HM.
europepmc   +1 more source

Enhancing AI Research for Breast Cancer: A Comprehensive Review of Tumor-Infiltrating Lymphocyte Datasets. [PDF]

J Imaging Inform Med
Fiorin A, López Pablo C, Lejeune M, Hamza Siraj A, Della Mea V.   +4 more
europepmc   +1 more source

Divergent transcriptional states and kinetics of circulating tumor-infiltrating lymphocyte repertoires with highly homologous T-cell receptor sequences in a patient during immunotherapy. [PDF]

J Immunother Cancer
Kajihara R, Long MD, Hoki T, Chen H, Yamauchi T, Kanemaru H, Segal BH, Dy GK, Ito F.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tumor-Infiltrating Lymphocyte Therapy in Advanced Melanoma

New England Journal of Medicine, 2023
Maartje W, Rohaan, Rob, Kessels, John B A G, Haanen   +2 more
exaly   +4 more sources

Tumor-Infiltrating Lymphocytes

The Cancer Journal, 2015
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) in combination with lymphodepletion and high-dose interleukin 2 has shown reproducible objective response rates of approximately 50% in patients with highly advanced, refractory metastatic melanoma.
Michal J, Besser, Ronnie, Shapira-Frommer, Jacob, Schachter   +2 more
openaire   +3 more sources